N-[2-[2-(Dimethylamino)Ethyl-Methylamino]-5-[[4-(1-Methylindol-3-Yl)Pyrimidin-2-Yl]Amino]-6-(2,2,2-Trifluoroethoxy)Pyridin-3-Yl]Prop-2-Enamide

2 trials 1 recruiting

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

5 Countries

Phase III

Phase III: 2

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer 1

Sponsors using this IMP

Arrivent Biopharma Inc. 2

All trials

2 total

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Part… Recruiting

2025-522151-26-00 Phase III 4 countries Arrivent Biopharma Inc.
A STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH NON-SMALL CEL… Ended

2022-502977-41-00 Phase III 4 countries Arrivent Biopharma Inc.

Showing 1–2 of 2 trials

← All drugs A–Z